Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONSHOHOCKEN, PA., FEB. 17, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON FEBRUARY 15, 2026 TO FIVE NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

SUZHOU, CHINA AND MLNDAL, SWEDEN, FEB. 11, 2026 /PRNEWSWIRE/ -- SUZHOU RIBO LIFE SCIENCE CO., LTD. (HKEX: 06938) ("RIBO") AND ITS SUBSIDIARY RIBOCURE PHARMACEUTICALS AB ("RIBOCURE") TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) ("MADRIGAL") FOR SIX PRE-CLINICAL SMALL INTERFERING RNA (SIRNA) PROGRAMS FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH).

RIBO AND RIBOCURE ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH MADRIGAL FOR NOVEL SIRNA THERAPEUTICS TARGETING MASH

CONSHOHOCKEN, PA., FEB. 11, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED AN EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SUZHOU RIBO LIFE SCIENCE CO. LTD. (RIBO) AND ITS SUBSIDIARY RIBOCURE PHARMACEUTICALS AB (RIBOCURE) FOR SIX PRECLINICAL SMALL INTERFERING RNA (SIRNA) PROGRAMS. SIRNAS OFFER A PRECISION APPROACH TO GENE SILENCING IN MASH BY SELECTIVELY REDUCING THE PRODUCTION OF DISEASE-DRIVING PROTEINS.

MADRIGAL EXPANDS ITS MASH PIPELINE WITH EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR SIX PRECLINICAL SIRNA PROGRAMS

CONSHOHOCKEN, PA., FEB. 05, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON FEBRUARY 1, 2026 TO 21 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN.

CONSHOHOCKEN, PA., FEB. 02, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) ANNOUNCED TODAY THAT IT WILL RELEASE ITS FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS ON THURSDAY, FEB. 19, 2026, PRIOR TO THE OPEN OF THE U.S. FINANCIAL MARKETS.

MADRIGAL PHARMACEUTICALS TO RELEASE FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND HOST WEBCAST ON FEBRUARY 19, 2026

CONSHOHOCKEN, PA., JAN. 22, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON JANUARY 15, 2026 TO 40 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., JAN. 21, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED AN EQUITY AWARD ON JANUARY 15, 2026 TO RITA THAKKAR, THE COMPANY'S NEW CHIEF ACCOUNTING OFFICER, AS AN EQUITY INDUCEMENT AWARD UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARD WAS APPROVED BY MADRIGAL'S BOARD OF DIRECTORS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

MADRIGAL PHARMACEUTICALS ANNOUNCES GRANT OF INDUCEMENT AWARD UNDER NASDAQ LISTING RULE 5635(C)(4)

CONSHOHOCKEN, PA., JAN. 09, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED AN EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH PFIZER FOR ERVOGASTAT, A CLINICAL-STAGE ORAL DGAT-2 INHIBITOR, STRENGTHENING THE COMPANY'S LEADERSHIP IN SHAPING THE NEXT GENERATION OF MASH THERAPIES AND COMBINATION REGIMENS. DGAT-2 INHIBITORS WORK BY BLOCKING THE FINAL STEP IN TRIGLYCERIDE ASSEMBLY AND STORAGE, RESULTING IN LOWER HEPATIC TRIGLYCERIDES, REDUCED LIPOTOXIC FAT AND DECREASED INFLAMMATION IN THE LIVER.

MADRIGAL EXPANDS ITS MASH PIPELINE WITH EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR ERVOGASTAT, A PHASE 2 ORAL DGAT-2 INHIBITOR

CONSHOHOCKEN, PA., DEC. 18, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON DECEMBER 15, 2025 TO 4 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., DEC. 15, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE J.P. MORGAN ANNUAL HEALTHCARE CONFERENCE ON MONDAY, JANUARY 12, 2026 AT 1:30PM PST.

MADRIGAL PHARMACEUTICALS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

CONSHOHOCKEN, PA., DEC. 04, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON DECEMBER 1, 2025 TO 24 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Madrigal Pharmaceuticals, Inc.

MDGL

Price

Financial Reports

No items found.

Press Releases

Madrigal Pharmaceuticals, Inc.

MDGL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MDGL